双极性抑郁症患者的低剂量互白素-2:一个2期随机双盲安慰剂对照试验
Marion Leboyer1, Marianne Foiselle1, Nicolas Tchitchek2
1Université Paris Est Créteil (UPEC), AP-HP, Department of Psychiatry, Hôpital Henri Mondor, DMU IMPACT, FHU ADAPT, INSERM U955, IMRB, Translational NeuroPsychiatry Laboratory, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.
Brain, behavior, and immunity
|September 6, 2024
概括
低剂量插白素-2 (IL-2LD) 在双相抑郁症患者中安全刺激调节性T细胞 (Tregs). 这种免疫调节改善了抑郁症状和功能,支持炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 双极性障碍 (BD) 与免疫功能障碍有关,包括缺乏调节性T细胞 (Tregs) 和炎症标志物升高.
- Tregs对于免疫调节至关重要,这表明它们的刺激可能是双极性抑郁症的治疗策略.
研究的目的:
- 评估低剂量介白素-2 (IL-2LD) 作为双极性抑郁症的补充治疗的安全性和有效性.
- 评估IL-2LD能够刺激调节性T细胞 (Tregs) 和改善抑郁症状的能力.
主要方法:
- 一个随机,双盲,安慰剂控制的试验,涉及14名患有双相抑郁症的患者.
- 患者接受了安慰剂或IL-2LD5天,然后每周服用4周.
- 主要结局:测量Treg扩张通过Treg百分比从基线增加到第5天.
主要成果:
- 与安慰剂相比,IL-2LD显著扩大和激活Tregs (p=0.0421).与安慰剂相比,IL-2LD显著扩大和激活Tregs (p=0.0421).
- 接受IL-2LD治疗的患者从第15天起显著改善了抑郁症状和整体功能.
- 治疗耐受性良好,没有严重的不良事件归因于IL-2LD.
结论:
- IL-2LD是一种安全有效的方法,用于刺激双极性抑郁症患者的Tregs.
- 这种免疫调节方法在治疗双极性抑郁症方面表现有前途,突出了BD中炎症的作用.
- 需要进一步研究IL-2LD作为情绪障碍的辅助治疗.
相关概念视频
Bipolar Disorder
60
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
60
Mania and Antimanic Drugs: Overview
155
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
155
Electroconvulsive Therapy
29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205


